Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03691064 · ClinicalTrials.gov registry record
Post-Authorization Long-Term Safety Study of LUTATHERA
A clinical trial of Neuroendocrine Tumors, sponsored by Advanced Accelerator Applications.
- Active
- Registry status
- 1,014
- Enrollment target
- 20
- Study locations
NCT03691064 is a study of Neuroendocrine Tumors that is active but no longer recruiting, run by Advanced Accelerator Applications. The registered enrollment target is 1,014 participants, above the 160-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (534% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT03691064, a study of Neuroendocrine Tumors, is active but no longer recruiting, sponsored by Advanced Accelerator Applications.
- ACTIVE NOT RECRUITING
- Registry status
- 1,014 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study to assess the long-term safety of LUTATHERA for the labeled indication (SmPC/USPI).
Conditions Studied
Interventions
- DRUG LUTATHERA
Study Locations (20)
Other
- Novartis Investigative site - Clichy
- Novartis Investigative site - Lyon
- Novartis Investigative site - Villejuif
- Novartis Investigative site - Birmingham
- Novartis Investigative site - Cambridge
- Novartis Investigative site - Glasgow
- Novartis Investigative site - Liverpool
- Novartis Investigative site - London
- Novartis Investigative site - London
- Novartis Investigative site - London
- Novartis Investigative site - London
- Novartis Investigative site - Manchester
- Novartis Investigative site - Sheffield
Arizona
- Banner MD Anderson Cancer Center - Phoenix
Ohio
- The Ohio State University Wexner Medical Center - Portland
Oregon
- Oregon Health & Sciences University Hospital - Portland
Washington
- Virginia Mason in Seattle - Seattle
Coimbra District
- Novartis Investigative site - Coimbra
La Corunya
- Novartis Investigative site - Santiago de Compostela
Madrid
- Novartis Investigative site - Majadahonda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,014 participants |
| Start Date | 2018-11-28 |
| Est. Completion | 2027-09-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03691064
The ClinicalTrials.gov registry entry for NCT03691064 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,014 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 160-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (534% higher). The listed sponsor is Advanced Accelerator Applications, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 1 intervention - of which LUTATHERA is the first listed.
NCT03691064 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Arizona, Ohio.
Frequently Asked Questions
What is clinical trial NCT03691064 about?
NCT03691064 is a clinical study titled "Post-Authorization Long-Term Safety Study of LUTATHERA". Study to assess the long-term safety of LUTATHERA for the labeled indication (SmPC/USPI).
What is the current status of trial NCT03691064?
This trial is currently active not recruiting. The enrollment target is 1,014 participants. The study started on 2018-11-28. Estimated completion is 2027-09-30.
What conditions does trial NCT03691064 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors.
What interventions are being tested in trial NCT03691064?
The interventions under investigation include: LUTATHERA (DRUG).
Who is sponsoring clinical trial NCT03691064?
This trial is sponsored by Advanced Accelerator Applications, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03691064 being conducted?
This trial has 20 study locations across Arizona, Ohio, Oregon, Washington, Coimbra District. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RECRUITING · Phase 1
-
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
RECRUITING · Phase 1
-
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
RECRUITING · Phase 2
-
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.